US2021177802A1PendingUtilityA1

Pharmaceutical composition for treating tumor

62
Assignee: EISAI R&D MAN CO LTDPriority: Jul 26, 2019Filed: Feb 19, 2021Published: Jun 17, 2021
Est. expiryJul 26, 2039(~13 yrs left)· nominal 20-yr term from priority
Inventors:Taro SembaYasuhiro Funahashi
C07K 2317/73C07K 16/2818A61K 39/39558A61K 39/39541A61K 31/357A61K 9/1271A61K 2300/00A61K 45/06A61K 2039/505A61P 35/00A61K 45/00A61P 35/04A61K 9/127
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed herein is a method for treating tumor, comprising administering a liposomal composition comprising eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist to a patient in need thereof.

Claims

exact text as granted — not AI-modified
1 - 7 . (canceled) 
     
     
         8 . A method for treating a tumor, comprising administering a liposomal composition comprising eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist to a patient in need thereof, wherein the PD-1 antagonist is an anti-PD-1 antibody, and wherein the tumor is selected from the group consisting of gastric cancer, esophageal cancer, and small cell lung cancer. 
     
     
         9 . The method according to  claim 8 , wherein the liposomal composition comprising eribulin or a pharmaceutically acceptable salt thereof and the PD-1 antagonist are administered simultaneously. 
     
     
         10 . The method according to  claim 8 , wherein the liposomal composition comprising eribulin or a pharmaceutically acceptable salt thereof and the PD-1 antagonist are administered separately. 
     
     
         11 . The method according to  claim 8 , wherein eribulin or the pharmaceutically acceptable salt thereof is eribulin mesylate. 
     
     
         12 . The method according to  claim 8 , wherein the anti-PD-1 antibody is selected from the group consisting of nivolumab, pembrolizumab, cemiplimab, sintilimab, and toripalimab. 
     
     
         13 . The method according to  claim 8 , wherein the tumor is gastric cancer. 
     
     
         14 . The method according to  claim 12 , wherein the tumor is gastric cancer. 
     
     
         15 . The method according to  claim 8 , wherein the tumor is esophageal cancer. 
     
     
         16 . The method according to  claim 12 , wherein the tumor is esophageal cancer. 
     
     
         17 . The method according to  claim 8 , wherein the tumor is small cell lung cancer. 
     
     
         18 . The method according to  claim 12 , wherein the tumor is small cell lung cancer. 
     
     
         19 . The method according to  claim 12 , wherein eribulin or the pharmaceutically acceptable salt thereof is eribulin mesylate. 
     
     
         20 . The method according to  claim 13 , wherein eribulin or the pharmaceutically acceptable salt thereof is eribulin mesylate. 
     
     
         21 . The method according to  claim 14 , wherein eribulin or the pharmaceutically acceptable salt thereof is eribulin mesylate. 
     
     
         22 . The method according to  claim 15 , wherein eribulin or the pharmaceutically acceptable salt thereof is eribulin mesylate. 
     
     
         23 . The method according to  claim 16 , wherein eribulin or the pharmaceutically acceptable salt thereof is eribulin mesylate. 
     
     
         24 . The method according to  claim 17 , wherein eribulin or the pharmaceutically acceptable salt thereof is eribulin mesylate. 
     
     
         25 . The method according to  claim 18 , wherein eribulin or the pharmaceutically acceptable salt thereof is eribulin mesylate.

Join the waitlist — get patent alerts

Track US2021177802A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.